BMS-833923 100 mg | 99.61%
TargetMol
BMS-833923, an orally bioavailable Smoothened antagonist, inhibits BODIPY cyclopamine binding to SMO in a dose-dependent manner (IC50: 21 nM).
More Information Supplier PageBMS-833923
Search Results
BMS-833923 10 mg | 99.61%
TargetMol
BMS-833923, an orally bioavailable Smoothened antagonist, inhibits BODIPY cyclopamine binding to SMO in a dose-dependent manner (IC50: 21 nM).
More Information Supplier PageBMS-833923
Brexpiprazole 100 mg | 99.69%
TargetMol
Brexpiprazole is a partial agonist of human 5-hydroxytryptamine (5-HT) 5-HT1A and dopamine D2 receptors.
More Information Supplier PageBrexpiprazole
SP2509 5 mg | 99.49%
TargetMol
SP2509 is a specific histone demethylase LSD1 inhibitor(IC50 =13 nM).
More Information Supplier PageSP2509
SP2509 50 mg | 99.49%
TargetMol
SP2509 is a specific histone demethylase LSD1 inhibitor(IC50 =13 nM).
More Information Supplier PageSP2509
SP2509 10 mg | 99.49%
TargetMol
SP2509 is a specific histone demethylase LSD1 inhibitor(IC50 =13 nM).
More Information Supplier PageSP2509
SP2509 100 mg | 99.49%
TargetMol
SP2509 is a specific histone demethylase LSD1 inhibitor(IC50 =13 nM).
More Information Supplier PageSP2509
BMS-833923 50 mg | 99.61%
TargetMol
BMS-833923, an orally bioavailable Smoothened antagonist, inhibits BODIPY cyclopamine binding to SMO in a dose-dependent manner (IC50: 21 nM).
More Information Supplier PageBMS-833923
BMS-833923 25 mg | 99.61%
TargetMol
BMS-833923, an orally bioavailable Smoothened antagonist, inhibits BODIPY cyclopamine binding to SMO in a dose-dependent manner (IC50: 21 nM).
More Information Supplier PageBMS-833923
TH287 2 mg | 97.73%
TargetMol
TH287 is a potent inhibitor of MTH1 (NUDT1), less potent for MTH2, NUDT5, NUDT12, NUDT14, and NUDT16.
More Information Supplier PageTH287
